The Development of Novel Therapies for Rheumatoid Arthritis
about
Development of macromolecular prodrug for rheumatoid arthritisOptimization and pharmacological validation of a leukocyte migration assay in zebrafish larvae for the rapid in vivo bioactivity analysis of anti-inflammatory secondary metabolitesPharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model.Therapeutic effects of matrine derivate MASM in mice with collagen-induced arthritis and on fibroblast-like synoviocytes.Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.Toxicity profile of a nutraceutical formulation derived from green mussel Perna viridis.Emerging roles of SUMO modification in arthritis.The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in ratsNanostructured lipid carriers based nanogel for meloxicam delivery: mechanistic, in-vivo and stability evaluation.Total flavonoids of Bidens bipinnata L. ameliorate experimental adjuvant-induced arthritis through induction of synovial apoptosis.A practical guide about biosimilar data for health care providers treating inflammatory diseasesA biphasic effect of TNF-α in regulation of the Keap1/Nrf2 pathway in cardiomyocytes.Nanocarriers for vascular delivery of anti-inflammatory agentsNovel insights into Tim-4 function in autoimmune diseases.Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Analysis of patents on anti-rheumatoid arthritis therapies issued in China.Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects.Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.S100-alarmins: potential therapeutic targets for arthritis.An unprecedented antioxidative isopimarane norditerpenoid from bivalve clam, Paphia malabarica with anti-cyclooxygenase and lipoxygenase potential.Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study.Dextromethorphan Exhibits Anti-inflammatory and Immunomodulatory Effects in a Murine Model of Collagen-Induced Arthritis and in Human Rheumatoid ArthritisTherapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis.Protection against osteoarthritis in experimental animals by nanogold conjugated snake venom protein toxin gold nanoparticle-Naja kaouthia cytotoxin 1.Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib.Current concepts in the genetic diagnostics of rheumatoid arthritis.An Important Role for N-Acylethanolamine Acid Amidase in the Complete Freund's Adjuvant Rat Model of Arthritis.Majoon ushba, a polyherbal compound, suppresses pro-inflammatory mediators and RANKL expression via modulating NFкB and MAPKs signaling pathways in fibroblast-like synoviocytes from adjuvant-induced arthritic rats.Location and gene-specific effects of methylprednisolone acetate on mitigating IL1β-induced inflammation in mature ovine explant knee tissue.Silica-coated solid lipid nanoparticles enhance antioxidant and antiradical effects of meloxicamApplication of liposomes in treatment of rheumatoid arthritis: quo vadis
P2860
Q27693332-BC626168-18B1-4693-8A0A-13F5CFB34F7DQ28534106-FF117D08-B3B5-42E2-B88D-9FC676823427Q30495832-A5AF07CD-CBB6-4A51-820B-C308029257F5Q33732804-2CEAFE89-E067-4EC3-98AF-643B21A80410Q33754764-F74DF621-0A5B-4056-B32C-856C39B6942AQ33790838-9C5D415E-52B0-48B8-B3BB-2D0E18BE89BDQ34108064-A0608317-852C-4646-A691-DB7210ECB184Q35216463-C8F30FBA-60B6-4857-8653-2D5BA0DDC978Q35230563-1E26DD69-1446-43AF-91B0-A79133FE01E4Q35869132-CF48A9EE-7B7E-4E1D-8283-4BA36C626A37Q36303459-6257C54A-1759-4712-BE29-891947BCDADCQ37127124-68AA573B-C9ED-441E-84C8-7ED4297EA97BQ38176037-D81C8B69-1A12-4DED-BD8D-7E35580FA1ADQ38282253-A7819312-91B2-419F-B54E-BADAB0C544F6Q38305522-6F3CD37A-3159-424D-8C18-A988C35BB11DQ38525320-7FBE2899-486A-4AB0-AB26-4E7D0CF53ADAQ38543383-501BE8EC-E5A6-453D-BBC0-C4D41ECB42F3Q38684930-A3927246-8BD6-4BDA-AA5B-2151ED65A113Q38685009-9BB5547A-19C7-4636-9621-C3BF62051FF3Q38766505-FE49542B-399D-45A3-9F8C-F08C8ACD38CDQ38957340-534E3147-DBAF-4E89-81CC-0DB1A3BEFEBEQ39151076-43F0AB29-1E5A-4105-8FF0-449E1416BFEFQ41200262-C1DBC674-C9D5-49F4-8735-14E2A6BDAED6Q42107547-6A1C3E37-9497-4DD6-AA58-771D8C3B971EQ42263911-68C0AB0C-4DDC-498B-A11F-930ECBDC9004Q42537908-54683EEA-C2E3-425E-9219-01ACC756CFDCQ42970803-481F3C82-F513-418E-B0CF-FAD6AADD7AABQ46629227-3DD66EF8-7B95-4B19-B404-C7A48662C921Q50862393-FB64625E-802D-4A07-8050-8133156647FAQ51099342-A1D794EB-A478-49FB-9C74-A91C8D39895FQ57591281-A1C056B9-CBF0-4117-B121-CF6A97375F8BQ59101195-657F143D-5A2E-42D9-8B8A-634816FBA6A8
P2860
The Development of Novel Therapies for Rheumatoid Arthritis
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The Development of Novel Therapies for Rheumatoid Arthritis
@ast
The Development of Novel Therapies for Rheumatoid Arthritis
@en
type
label
The Development of Novel Therapies for Rheumatoid Arthritis
@ast
The Development of Novel Therapies for Rheumatoid Arthritis
@en
prefLabel
The Development of Novel Therapies for Rheumatoid Arthritis
@ast
The Development of Novel Therapies for Rheumatoid Arthritis
@en
P2093
P2860
P1476
The Development of Novel Therapies for Rheumatoid Arthritis
@en
P2093
Geoffrey M Thiele
Ling-Dong Quan
P2860
P304
P356
10.1517/13543776.18.7.723
P407
P577
2008-07-01T00:00:00Z